Products & Services · Total revenues
C5 License Obligation — Total revenues
Alnylam Pharmaceuticals C5 License Obligation — Total revenues decreased by 100.0% to $0 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $21.48M to $0. Over 4 years (FY 2021 to FY 2025), C5 License Obligation — Total revenues shows a downward trend with a -16.4% CAGR.
Analysis
Metric ID:
alny_segment_c5_license_obligation_total_revenuesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.7M | $1.2M | $14.2M | $1.3M | -$4.8M | $1.4M | $34.6M | $2.2M | $3.1M | $700K | -$21.1M | $1.7M | $8.8M | $8.4M | $19.44M | $21.48M | $0 | $0 | $265K | $0 |
| QoQ Change | — | -92.4% | >999% | -90.8% | -469.2% | +129.2% | >999% | -93.6% | +40.9% | -77.4% | <-999% | +108.1% | +417.6% | -4.5% | +131.4% | +10.5% | -100.0% | — | — | -100.0% |
| YoY Change | — | — | — | — | -130.6% | +16.7% | +143.7% | +69.2% | +164.6% | -50.0% | -161.0% | -22.7% | +183.9% | >999% | +192.1% | >999% | -100.0% | -100.0% | -98.6% | -100.0% |
Range-$21.1M – $34.6M
CAGR-100.0%
Avg YoY Growth+141.9%
Median YoY Growth-3.0%
Current Streak4 quarters decline
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's c5 license obligation — total revenues?
- Alnylam Pharmaceuticals (ALNY) reported c5 license obligation — total revenues of $0 in Q1 2026.
- How has Alnylam Pharmaceuticals's c5 license obligation — total revenues changed year-over-year?
- Alnylam Pharmaceuticals's c5 license obligation — total revenues decreased by 100.0% year-over-year, from $21.48M to $0.
- What is the long-term trend for Alnylam Pharmaceuticals's c5 license obligation — total revenues?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's c5 license obligation — total revenues has grown at a -16.4% compound annual growth rate (CAGR), from $44.6M to $21.74M.